The role of day 0 and day 4 β-human chorionic gonadotropin values and initial ultrasound findings in predicting the success of methotrexate treatment in ectopic pregnancy
, 2, 1, 1, 1
Abstract
Objectives: To determine the role of baseline ultrasound findings and the changes between β- human chorionic gonadotropin
(hCG) values on day 0 to day 4 in patients receiving single-dose methotrexate (MTX) therapy for tubal ectopic pregnancy.
Material and methods: One hundred fourteen patients who were hospitalized with a diagnosis of ectopic pregnancy and
treated with single-dose methotrexate were included in this retrospective study. The successful treatment group (n = 88)
comprised patients in whom serum β-hCG levels were resolved with single-dose methotrexate treatment, and the failed
treatment group (n = 26) included patients who received second dose methotrexate and/or surgery. Ultrasound findings,
laboratory findings, and serum β-hCG values at the time of admission and D4 and D7 β-hCG values were compared.
Results: The success rate of single-dose methotrexate treatment was 77.2%. In the successful treatment group, the initial
β-hCG values of the patients were lower than the unsuccessful treatment group (1479.14 ± 1253.49, 4442.88 ± 3392.58,
respectively) (p = 0.0001). A decrease of more than 35% between D0-D4 increased the probability of successful treatment
(p = 0.017). Although ectopic focus size and abdominal free fluid showed no significant difference between the two groups,
endometrial stripe thickness was significantly higher in the unsuccessful treatment group (12.61 ± 5.79, 9.28 ± 3.53) (p = 0.002).
Conclusions: In addition to the basal β-hCG value, endometrial stripe thickness of ultrasound findings should also be
considered in determining patients with a high chance of success in single-dose MTX treatment.β-hCG changes between
D0-D4 may be advantageous in the clinical management of ectopic pregnancy for earlier evaluation.
Keywords: ectopic pregnancymethotrexateserum β-hCGtreatment success
References
- Bouyer J, Coste J, Fernandez H, et al. Sites of ectopic pregnancy: a 10 year population-based study of 1800 cases. Hum Reprod. 2002; 17(12): 3224–3230.
- Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance--United States, 1991--1999. MMWR Surveill Summ. 2003; 52(2): 1–8.
- Shaw JLV, Dey SK, Critchley HOD, et al. Current knowledge of the aetiology of human tubal ectopic pregnancy. Hum Reprod Update. 2010; 16(4): 432–444.
- Barnhart KT, Gosman G, Ashby R, et al. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. Obstet Gynecol. 2003; 101(4): 778–784.
- Glock J, Johnson J, Brumsted J. Efficacy and safety of single-dose systemic methotrexate in the treatment of ectopic pregnancy. Fertility and Sterility. 1994; 62(4): 716–721.
- Tanaka T, Hayashi H, Kutsuzawa T, et al. Treatment of interstitial ectopic pregnancy with methotrexate: report of a successful case. Fertility and Sterility. 1982; 37(6): 851–852.
- Hajenius PJ, Mol F, Mol BWJ, et al. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev. 2007(1): CD000324.
- Prevost RR, Stovall TG, Ling FW, et al. Single-dose methotrexate for treatment of ectopic pregnancy. Obstet Gynecol. 1991; 77(5): 754–757.
- Kirk E, Condous G, Van Calster B, et al. A validation of the most commonly used protocol to predict the success of single-dose methotrexate in the treatment of ectopic pregnancy. Hum Reprod. 2007; 22(3): 858–863.
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 94: Medical management of ectopic pregnancy. Obstet Gynecol. 2008; 111(6): 1479–1485.
- Cobellis G, Pierno G, Pecori E, et al. Methotrexate treatment for tubal pregnancy. Criteria for medical approach. Minerva Ginecol. 2003; 55(6): 531–535.
- Kimiaei P, Khani Z, Marefian A, et al. The importance of gestational sac size of ectopic pregnancy in response to single-dose methotrexate. ISRN Obstet Gynecol. 2013; 2013: 269425.
- Ustunyurt E, Duran M, Coskun E, et al. Role of initial and day 4 human chorionic gonadotropin levels in predicting the outcome of single-dose methotrexate treatment in women with tubal ectopic pregnancy. Arch Gynecol Obstet. 2013; 288(5): 1149–1152.
- Gunay T, Yardımcı OD, Hocaoğlu M, et al. Factors Affecting Success of Single-Dose Methotrexate Treatment in Ectopic Pregnancy. Kocaeli Med J. 2019; 8(1): 189–194.
- Gnisci A, Stefani L, Bottin P, et al. Predictive value of hemoperitoneum for outcome of methotrexate treatment in ectopic pregnancy: an observational comparative study. Ultrasound Obstet Gynecol. 2014; 43(6): 698–701.
- Lipscomb GH, McCord ML, Stovall TG, et al. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med. 1999; 341(26): 1974–1978.
- Sickler GK, Chen PC, Dubinsky TJ, et al. Free echogenic pelvic fluid: correlation with hemoperitoneum. J Ultrasound Med. 1998; 17(7): 431–435.
- Sargin MA, Yassa M, Taymur BD, et al. A Clinical Experience of Ectopic Pregnancies with Initial Free Intraperitoneal Fluid. J Clin Diagn Res. 2016; 10(8): QC22–QC26.
- da Costa Soares R, Elito J, Han KK, et al. Endometrial thickness as an orienting factor for the medical treatment of unruptured tubal pregnancy. Acta Obstet Gynecol Scand. 2004; 83(3): 289–292.
- Takacs P, Chakhtoura N, De Santis T, et al. Evaluation of the relationship between endometrial thickness and failure of single-dose methotrexate in ectopic pregnancy. Arch Gynecol Obstet. 2005; 272(4): 269–272.
- da Costa Soares R, Elito J, Camano L. Increment in beta-hCG in the 48-h period prior to treatment: a new variable predictive of therapeutic success in the treatment of ectopic pregnancy with methotrexate. Arch Gynecol Obstet. 2008; 278(4): 319–324.
- Rabischong B, Tran X, Sleiman AA, et al. Predictive factors of failure in management of ectopic pregnancy with single-dose methotrexate: a general population-based analysis from the Auvergne Register, France. Fertil Steril. 2011; 95(1): 401–4, 404.e1.
- Nowak-Markwitz E, Michalak M, Olejnik M, et al. Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy. Fertil Steril. 2009; 92(4): 1203–1207.
- Pulatoglu C, Dogan O, Basbug A, et al. Predictive factors of methotrexate treatment success in ectopic pregnancy: A single-center tertiary study. North Clin Istanb. 2018; 5(3): 227–231.
- Corsan GH, Karacan M, Qasim S, et al. Identification of hormonal parameters for successful systemic single-dose methotrexate therapy in ectopic pregnancy. Hum Reprod. 1995; 10(10): 2719–2722.
- Levin G, Dior U, Shushan A, et al. Early prediction of the success of methotrexate treatment success by 24-hour pretreatment increment in HCG and day 1-4 change in HCG. Reprod Biomed Online. 2019; 39(1): 149–154.
- Rong-Hao L, Luo S, Zhuang LZ. Establishment and characterization of a cytotrophoblast cell line from normal placenta of human origin. Hum Reprod. 1996; 11(6): 1328–1333.
- Nguyen Q, Kapitz M, Downes K, et al. Are early human chorionic gonadotropin levels after methotrexate therapy a predictor of response in ectopic pregnancy? Am J Obstet Gynecol. 2010; 202(6): 630.e1–630.e5.
- Skubisz MM, Li J, Lee J, et al. Decline in βhCG levels between days 0 and 4 after a single dose of methotrexate for ectopic pregnancy predicts treatment success: a retrospective cohort study. BJOG. 2011; 118(13): 1665–1668.
- Agostini A, Blanc K, Ronda I, et al. Prognostic value of human chorionic gonadotropin changes after methotrexate injection for ectopic pregnancy. Fertil Steril. 2007; 88(2): 504–506.
- Mashiach R, Kislev I, Gilboa D, et al. Significant increase in serum hCG levels following methotrexate therapy is associated with lower treatment success rates in ectopic pregnancy patients. Eur J Obstet Gynecol Reprod Biol. 2018; 231: 188–191.
- Brunello J, Guerby P, Cartoux C, et al. Can early βhCG change and baseline progesterone level predict treatment outcome in patients receiving single dose Methotrexate protocol for tubal ectopic pregnancy? Arch Gynecol Obstet. 2019; 299(3): 741–745.
